| (19) |
 |
|
(11) |
EP 3 978 522 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
06.07.2022 Bulletin 2022/27 |
| (43) |
Date of publication A2: |
|
06.04.2022 Bulletin 2022/14 |
| (22) |
Date of filing: 02.05.2013 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
| (30) |
Priority: |
03.05.2012 US 201261642083 P
24.10.2012 US 201261718044 P
14.03.2013 US 201361783312 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
19218187.3 / 3660047 |
|
13721544.8 / 2844672 |
| (71) |
Applicant: Regeneron Pharmaceuticals, Inc. |
|
Tarrytown, NY 10591-6707 (US) |
|
| (72) |
Inventors: |
|
- ORENGO, Jamie
Cortlandt Manor, 10567 (US)
- MURPHY, Andrew J.
Croton-on-Hudson, 10520 (US)
|
| (74) |
Representative: J A Kemp LLP |
|
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB) |
|
| |
|
| (54) |
HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF |
(57) The present invention provides antibodies that bind to the cat allergen, Fel d1,
compositions comprising the antibodies, nucleic acids encoding the antibodies and
methods of use of the antibodies. According to certain embodiments of the invention,
the antibodies are fully human monoclonal antibodies that bind to Fel d1. The antibodies
of the invention are useful for binding to the Fel d1 allergen
in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of
mast cells or basophils. In doing so, the antibodies act to prevent the release of
histamine and other inflammatory mediators from mast cells and/or basophils, thus
ameliorating the untoward response to the cat allergen in sensitized individuals.
The antibodies of the invention may also be useful for diagnostic purposes to determine
if a patient is allergic to the Fel d1 cat allergen.